- Home
- ACRS vs HEQ Comparison
ACRS vs HEQ Comparison
Compare ACRS & HEQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- HEQ
- Stock Information
- Founded
- ACRS 2012
- HEQ 2011
- Country
- ACRS United States
- HEQ United States
- Employees
- ACRS N/A
- HEQ N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- HEQ Investment Managers
- Sector
- ACRS Health Care
- HEQ Finance
- Exchange
- ACRS Nasdaq
- HEQ Nasdaq
- Market Cap
- ACRS 132.0M
- HEQ 126.1M
- IPO Year
- ACRS 2015
- HEQ N/A
- Fundamental
- Price
- ACRS $2.72
- HEQ $10.27
- Analyst Decision
- ACRS Strong Buy
- HEQ
- Analyst Count
- ACRS 5
- HEQ 0
- Target Price
- ACRS $8.75
- HEQ N/A
- AVG Volume (30 Days)
- ACRS 1.1M
- HEQ 43.1K
- Earning Date
- ACRS 11-06-2024
- HEQ 01-01-0001
- Dividend Yield
- ACRS N/A
- HEQ 9.78%
- EPS Growth
- ACRS N/A
- HEQ N/A
- EPS
- ACRS N/A
- HEQ N/A
- Revenue
- ACRS $27,079,000.00
- HEQ N/A
- Revenue This Year
- ACRS N/A
- HEQ N/A
- Revenue Next Year
- ACRS N/A
- HEQ N/A
- P/E Ratio
- ACRS N/A
- HEQ N/A
- Revenue Growth
- ACRS 26.35
- HEQ N/A
- 52 Week Low
- ACRS $0.86
- HEQ $9.08
- 52 Week High
- ACRS $5.17
- HEQ $11.84
- Technical
- Relative Strength Index (RSI)
- ACRS 41.17
- HEQ 28.99
- Support Level
- ACRS $2.91
- HEQ $10.90
- Resistance Level
- ACRS $3.29
- HEQ $10.50
- Average True Range (ATR)
- ACRS 0.29
- HEQ 0.12
- MACD
- ACRS -0.18
- HEQ -0.08
- Stochastic Oscillator
- ACRS 0.75
- HEQ 13.30
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.